Neurocrine Plans to Lay Off Half Its Staff

Neurocrine Biosciences, maker of experimental drugs for treating neurological and endocrine disorders, said May 6 it would cut its 120-person staff in half to conserve cash as it focuses on moving its midstage clinical programs into final Phase 3 trials...

Take 1 minute to subscribe and you'll get this story immediately, plus: